Overall survival between veterans with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone with kidney disease.

被引：0

作者：

Wilson, Robert

Doherty, Jason M.

Luo, Suhong

Candelieri-Surette, Danielle

Eaton Jr, Daniel B.

Schoen, Martin W.

机构：

[1] St Louis Univ, Sch Med, St Louis, MO USA

[2] St Louis Univ, Dept Hlth & Clin Outcomes Res, St Louis, MO USA

[3] St Louis VA Med Ctr, St Louis, MO USA

[4] Univ Massachusetts Lowell, Lowell, MA USA

[5] VA St Louis Hlth Care Syst, St Louis, MO USA

[6] St Louis Vet Affairs Med Ctr, St Louis, MO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.5_suppl.76

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[41] Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
Matsubara, Nobuaki
Yamada, Yoko
Tabata, Ken-ichi
Satoh, Takefumi
Kamiya, Naoto
Suzuki, Hiroyoshi
Kawahara, Takashi
Uemura, Hiroji
Yano, Akihiro
Kawakami, Satoru
Otsuka, Masafumi
Fukasawa, Satoshi
CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 142 - 148
[42] Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer
De Laere, Bram
Oeyen, Steffi
Van Oyen, Peter
Ghysel, Christophe
Ampe, Jozef
Ost, Piet
Demey, Wim
Hoekx, Lucien
Schrijvers, Dirk
Brouwers, Barbara
Lybaert, Willem
Everaert, Els
Van Kerckhove, Piet
De Maeseneer, Daan
Strijbos, Michiel
Bols, Alain
Fransis, Karen
Beije, Nick
de Kruijff, Inge
van Dam, Valerie
Brouwer, Anja
van Dam, Pieter-Jan
Van den Eynden, Gert
Rutten, Annemie
Sleijfer, Stefan
Vandebroek, Jean
Van Laere, Steven
Dirix, Luc
PROSTATE, 2018, 78 (06): : 435 - 445
[43] Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel
Ryan, Charles J.
Dutta, Sandipan
Kelly, William K.
Middleberg, Rob
Russell, Carly
Morris, Michael J.
Taplin, Mary-Ellen
Halabi, Susan
CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : 222 - +
[44] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Mostaghel, Elahe A.
CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
[45] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Rodriguez-Vida, Alejo
Galazi, Myria
Rudman, Sarah
Chowdhury, Simon
Sternberg, Cora N.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
[46] Development of enzalutamide for metastatic castration-resistant prostate cancer
Bhattacharya, Suman
Hirmand, Mohammad
Phung, De
van Os, Steve
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 13 - 27
[47] The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide
Serrano Domingo, Juan Jose
Alonso Gordoa, Teresa
Lorca Alvaro, Javier
Molina-Cerrillo, Javier
Barquin Garcia, Arantzazu
Martinez Saez, Olga
Burgos Revilla, Javier
Carrato, Alfredo
Alvarez Rodriguez, Sara
THERAPEUTIC ADVANCES IN UROLOGY, 2021, 13
[48] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
Yang, Lily P. H.
DRUGS, 2011, 71 (15) : 2067 - 2077
[49] Abiraterone AcetateIn Metastatic Castration-Resistant Prostate Cancer
Lily P. H. Yang
Drugs, 2011, 71 : 2067 - 2077
[50] CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.
Tombal, Bertrand F.
Castellano, Daniel
Kramer, Gero
Eymard, Jean-Christophe
De Bono, Johann S.
Sternberg, Cora N.
Fizazi, Karim
Wulfing, Christian
Bamias, Aristotelis
Carles, Joan
Iacovelli, Roberto
Melichar, Bohuslav
Sverrisdottir, Asgerdur
Theodore, Christine
Feyerabend, Susan
Helissey, Carole
Poole, Elizabeth
Ozatilgan, Ayse
Geffriaud-Ricouard, Christine
De Wit, Ronald
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →